NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report issued on Monday,Benzinga reports. D. Boral Capital currently has a $31.00 price objective on the stock.

A number of other brokerages have also recently commented on NRXP. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. Ascendiant Capital Markets increased their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd.

NRx Pharmaceuticals Stock Down 0.5 %

NASDAQ NRXP opened at $2.07 on Monday. The firm has a 50-day moving average price of $2.77 and a two-hundred day moving average price of $2.04. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01. The company has a market capitalization of $35.02 million, a P/E ratio of -0.97 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). Equities analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Trading of NRx Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC acquired a new position in NRx Pharmaceuticals during the fourth quarter worth about $56,000. Millennium Management LLC bought a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at approximately $61,000. Anson Funds Management LP grew its holdings in shares of NRx Pharmaceuticals by 30.3% during the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after purchasing an additional 43,135 shares during the last quarter. AdvisorShares Investments LLC increased its position in NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after purchasing an additional 180,229 shares in the last quarter. Finally, Sassicaia Capital Advisers LLC bought a new position in NRx Pharmaceuticals in the 4th quarter valued at approximately $33,000. 4.27% of the stock is currently owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.